Related Experiment Video
Updated: Jul 14, 2026

Isolation and Identification of Waterborne Antibiotic-Resistant Bacteria and Molecular Characterization of their Antibiotic Resistance Genes
Published on: March 3, 2023
Class A carbapenemases
Jan Walther-Rasmussen1, Niels Høiby
1Department of Clinical Microbiology, 9301, Rigshospitalet, National University Hospital, Copenhagen, Denmark. jawalras@mail.tele.dk
Abstract:
Carbapenems, such as imipenem and meropenem, are most often used to treat infections caused by enterobacteria that produce extended-spectrum beta-lactamases, and the emergence of enzymes capable of inactivating carbapenems would therefore limit the options for treatment. Carbapenem resistance in Enterobacteriaceae is rare, but class A beta-lactamases with activity against the carbapenems are becoming more prevalent within this bacterial family. The class A carbapenemases can phylogenetically be segregated into six different groups of which four groups are formed by members of the GES, KPC, SME, IMI/NMC-A enzymes, while SHV-38 and SFC-1 each separately constitute a group. The genes encoding the class A carbapenemases are either plasmid-borne or located on the chromosome of the host. The bla(GES) genes reside as gene cassettes on mainly class I integrons, whereas the bla(KPC) genes and a single bla(IMI-2) gene are flanked by transposable elements on plasmids. Class A carbapenemases hydrolyse penicillins, classical cephalosporins, monobactam, and imipenem and meropenem, and the enzymes are divided into four phenotypically different groups, namely group 2br, 2be, 2e and 2f, according to the Bush-Jacoby-Medeiros classification system. Class A carbapenemases are inhibited by clavulanate and tazobactam like other class A beta-lactamases.
Insights
Carbapenem resistance in Enterobacteriaceae is rising due to prevalent class A beta-lactamases. These enzymes, like KPC and GES, inactivate carbapenems, limiting treatment options for serious infections.
Area of Science:
- Microbiology
- Molecular Biology
- Biochemistry
Background:
- Carbapenems (imipenem, meropenem) are crucial for treating infections caused by extended-spectrum beta-lactamase (ESBL)-producing enterobacteria.
- Emergence of carbapenem-inactivating enzymes threatens the efficacy of these last-resort antibiotics.
- Carbapenem resistance in Enterobacteriaceae, though rare, is increasing due to prevalent class A beta-lactamases.
Purpose of the Study:
- To review the classification and prevalence of class A carbapenemases in Enterobacteriaceae.
- To understand the genetic basis and location of carbapenemase genes.
- To discuss the enzymatic activity and inhibition of these resistance enzymes.
Main Methods:
- Phylogenetic analysis to classify class A carbapenemases.
- Review of genetic mechanisms (plasmid-borne, chromosomal, integrons, transposable elements).
- Enzymatic activity profiling and classification using the Bush-Jacoby-Medeiros system.
Main Results:
- Class A carbapenemases are phylogenetically grouped into six types (GES, KPC, SME, IMI/NMC-A, SHV-38, SFC-1).
- Genes encoding these enzymes are found on plasmids or chromosomes, often associated with mobile genetic elements like integrons and transposons.
- These enzymes hydrolyze various beta-lactams, including carbapenems, and are classified into four phenotypic groups (2br, 2be, 2e, 2f).
Conclusions:
- Class A carbapenemases are a growing threat to carbapenem efficacy in Enterobacteriaceae.
- Understanding their genetic and enzymatic diversity is crucial for surveillance and treatment strategies.
- These enzymes remain susceptible to inhibition by clavulanate and tazobactam, similar to other class A beta-lactamases.
Related Concept Videos
Clinical Significance of Antibiotic Resistance
Mechanism of Antibiotic Resistance in MRSA
Inhibitors of Gram-positive Cell Wall Synthesis
Development of Antibiotic Resistance
Gene Regulation in Microbial Communities: Quorum Sensing
Deep Sea Microbial Ecology
